These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
574 related articles for article (PubMed ID: 11244046)
1. The design of vaccines against Helicobacter pylori and their development. Del Giudice G; Covacci A; Telford JL; Montecucco C; Rappuoli R Annu Rev Immunol; 2001; 19():523-63. PubMed ID: 11244046 [TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Hatzifoti C; Roussel Y; Harris AG; Wren BW; Morrow JW; Bajaj-Elliott M Helicobacter; 2006 Apr; 11(2):113-22. PubMed ID: 16579841 [TBL] [Abstract][Full Text] [Related]
3. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Becher D; Deutscher ME; Simpfendorfer KR; Wijburg OL; Pederson JS; Lew AM; Strugnell RA; Walduck AK Eur J Immunol; 2010 Oct; 40(10):2778-90. PubMed ID: 21038469 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Rossi G; Ruggiero P; Peppoloni S; Pancotto L; Fortuna D; Lauretti L; Volpini G; Mancianti S; Corazza M; Taccini E; Di Pisa F; Rappuoli R; Del Giudice G Infect Immun; 2004 Jun; 72(6):3252-9. PubMed ID: 15155627 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Malfertheiner P; Selgrad M; Wex T; Romi B; Borgogni E; Spensieri F; Zedda L; Ruggiero P; Pancotto L; Censini S; Palla E; Kanesa-Thasan N; Scharschmidt B; Rappuoli R; Graham DY; Schiavetti F; Del Giudice G Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):698-707. PubMed ID: 30042064 [TBL] [Abstract][Full Text] [Related]
6. Advances in vaccination against Helicobacter pylori. Velin D; Michetti P Expert Rev Gastroenterol Hepatol; 2010 Apr; 4(2):157-66. PubMed ID: 20350263 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Liu KY; Shi Y; Luo P; Yu S; Chen L; Zhao Z; Mao XH; Guo G; Wu C; Zou QM Vaccine; 2011 Sep; 29(38):6679-85. PubMed ID: 21745524 [TBL] [Abstract][Full Text] [Related]
8. The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia. Arnold IC; Hitzler I; Engler D; Oertli M; Agger EM; Müller A J Immunol; 2011 Jun; 186(11):6165-72. PubMed ID: 21518972 [TBL] [Abstract][Full Text] [Related]
9. The current status of Helicobacter pylori vaccines: a review. Kabir S Helicobacter; 2007 Apr; 12(2):89-102. PubMed ID: 17309745 [TBL] [Abstract][Full Text] [Related]
11. Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on Guo L; Yang H; Tang F; Yin R; Liu H; Gong X; Wei J; Zhang Y; Xu G; Liu K Front Cell Infect Microbiol; 2017; 7():349. PubMed ID: 28824883 [TBL] [Abstract][Full Text] [Related]
12. Protection against Helicobacter pylori infection in BALB/c mice by oral administration of multi-epitope vaccine of CTB-UreI-UreB. Yang J; Dai LX; Pan X; Wang H; Li B; Zhu J; Li MY; Shi XL; Wang BN Pathog Dis; 2015 Jul; 73(5):. PubMed ID: 25846576 [TBL] [Abstract][Full Text] [Related]
13. Development of vaccines against Helicobacter pylori. Del Giudice G; Malfertheiner P; Rappuoli R Expert Rev Vaccines; 2009 Aug; 8(8):1037-49. PubMed ID: 19627186 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Malfertheiner P; Schultze V; Rosenkranz B; Kaufmann SH; Ulrichs T; Novicki D; Norelli F; Contorni M; Peppoloni S; Berti D; Tornese D; Ganju J; Palla E; Rappuoli R; Scharschmidt BF; Del Giudice G Gastroenterology; 2008 Sep; 135(3):787-95. PubMed ID: 18619971 [TBL] [Abstract][Full Text] [Related]
16. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Akhiani AA; Stensson A; Schön K; Lycke N Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008 [TBL] [Abstract][Full Text] [Related]
17. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice. Li X; Xing Y; Guo L; Lv X; Song H; Xi T Pathog Dis; 2014 Oct; 72(1):78-86. PubMed ID: 24687988 [TBL] [Abstract][Full Text] [Related]
18. Immunodominant epitope-specific Th1 but not Th17 responses mediate protection against Helicobacter pylori infection following UreB vaccination of BALB/c mice. Li B; Chen L; Sun H; Yang W; Hu J; He Y; Wei S; Zhao Z; Zhang J; Li H; Zou Q; Wu C Sci Rep; 2015 Oct; 5():14793. PubMed ID: 26434384 [TBL] [Abstract][Full Text] [Related]